Compare Gilead Sciences, Inc. (GILD) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Infosys Limited — how do they compare? Gilead Sciences, Inc. trades at $135.59 (market cap $163.51B), while Infosys Limited trades at $11.49 (market cap $46.19B). The key difference: Gilead Sciences, Inc. is far larger — about 3.5× Infosys Limited's market cap, and Infosys Limited pays the higher dividend (4.74%). Which is the better fit depends on your goals.
| GILD | INFY | |
|---|---|---|
Market Cap | $163.51B | $46.19B |
Sector | Health | Technology |
52-Week High | $155.80 | $20.22 |
52-Week Low | $108.22 | $10.49 |
Enterprise Value | $178.05B | $43.40B |
Dividend Yield | 2.49% | 4.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
INFY trades at $11.46, up 3.71% today, with a bearish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.23 beating expectations. Fundamentals show robust profitability with a net income margin of 16.44% and ROE of 31.57%, while valuation ratios like P/E of 13.8 and EV/EBITDA of 8.5 suggest reasonable pricing. Recent news highlights Infosys' expanding AI collaborations across healthcare, banking, and media sectors.
The outlook is mixed; analyst consensus is a 'Hold' with a $12.14 price target, implying modest upside. Strengths include solid cash flow and AI-driven growth initiatives, but risks involve competitive pressures in IT services and potential volatility from global tech spending trends. The stock presents a value opportunity with steady dividends, though investor sentiment remains cautious amid sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
